Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
5
Madrigal: Identifying, Managing and Treating Patients with NASH and Significant Fibrosis – Current Practice and Future Perspectives - ILC 2022
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: Unmasking NASH: the hepatic face of metabolic dysregulation - ILC 2021
View
Metabolism, Alcohol & Toxicity
5
Novo Nordisk: NASH – the metabolic disease of the liver - Digital ILC 2020
